Dyadic International (DYAI) Total Liabilities (2017 - 2026)
Dyadic International (DYAI) posted Total Liabilities of $8.2 million for Q1 2026, down 5.69% sequentially from $8.7 million in Q4 2025, and up 17.87% YoY from $7.0 million in Q1 2025.
Dyadic International (DYAI) Total Liabilities (2017 - 2026) Analysis & Trends
Dyadic International has reported Total Liabilities for 10 years, with the latest figure at $8.2 million in Q1 2026.
- Quarterly Total Liabilities rose 17.87% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (up 17.87% YoY) and the FY2025 annual result came in at $8.7 million, up 16.8% from the prior year.
- Total Liabilities eased to $8.2 million in Q1 2026 per DYAI's latest filing, from $8.7 million in the prior quarter.
- Over five years, Total Liabilities peaked at $2.1 billion in Q1 2022 and troughed at $1.6 million in Q3 2023.
- A 5-year average of $130.8 million and a median of $7.4 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities soared 7449.99% in 2022, then plunged 99.91% in 2023.
- Over 5 years, Total Liabilities stood at $2.6 million in 2022, then slipped by 10.84% to $2.3 million in 2023, then soared by 218.71% to $7.5 million in 2024, then rose by 16.8% to $8.7 million in 2025, then declined by 5.69% to $8.2 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $8.2 million, $8.7 million, and $9.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Dyadic International | 20.18 Mn | 20.18 Mn | - | 8.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.22 Mn |
| Dec 31, 2025 | 8.71 Mn |
| Sep 30, 2025 | 9.07 Mn |
| Jun 30, 2025 | 8.67 Mn |
| Mar 31, 2025 | 6.97 Mn |
| Dec 31, 2024 | 7.46 Mn |
| Sep 30, 2024 | 7.39 Mn |
| Jun 30, 2024 | 7.46 Mn |
| Mar 31, 2024 | 8.17 Mn |
| Dec 31, 2023 | 2.34 Mn |
| Sep 30, 2023 | 1.60 Mn |
| Jun 30, 2023 | 2.09 Mn |
| Mar 31, 2023 | 2.01 Mn |
| Dec 31, 2022 | 2.63 Mn |
| Sep 30, 2022 | 2.61 Mn |
| Jun 30, 2022 | 3.66 Mn |
| Mar 31, 2022 | 2.14 Bn |
| Dec 31, 2021 | 2.91 Mn |
| Sep 30, 2021 | 23.86 Mn |
| Jun 30, 2021 | 26.45 Mn |